echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Another drug consistency evaluation has been evaluated by 3 companies!

    Another drug consistency evaluation has been evaluated by 3 companies!

    • Last Update: 2019-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to pharmaceutical intelligence news, on November 26, Hyundai pharmaceutical released an enterprise announcement that indapamide tablets, a wholly-owned subsidiary of Shanghai Hyundai Pharmaceutical Group Industry Co., Ltd., passed the consistency evaluation and inquired the pharmaceutical intelligence data Sinopharm Co., Ltd was the third enterprise that passed the consistency evaluation of the product The formation of the tripartite confrontation Indapamide is a kind of sulfonamide diuretic, which has diuretic and calcium antagonistic effects It is a strong and long-acting antihypertensive drug, mainly used in the treatment of essential hypertension According to the data of PDB drug comprehensive database, the global sales of indapamide tablets in 2018 was $819 million, up 3.80% year on year According to the sales data of pharmaceutical intelligence hospital, from 2016 to 2019, the sales of indapamide tablets in domestic sample hospitals increased year by year, reaching 11.5222 million yuan in 2018, an increase of 18.87% year on year, of which Tianjin Lisheng pharmaceutical accounted for 56.45% At present, there are 32 market approvals for domestic indapamide tablets, involving 31 manufacturers, and 15 enterprises applying for acceptance of conformity assessment, among which Sinotech Co., Ltd is the third one Before that, Chongqing Yaoyou Pharmaceutical Co., Ltd and Guangdong anno Pharmaceutical Co., Ltd have reviewed the drugs of the same specification one after another Now, there is a three pronged trend and the competition pattern is intensified According to the announcement, the sales revenue of indapamide tablets (2.5mg) of Sinotech Co., Ltd in 2018 was about 42.15 million yuan Up to now, the cumulative input cost for consistency evaluation of indapamide tablets (2.5mg) is about 6.6 million yuan (Unaudited) Now the consistency evaluation has been made and the product quality and competitive advantage have been improved, which will be conducive to the future market sales and market competition of the product 37 statement: This article is to sort out the content, the viewpoint only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.